Adoptive T-cell therapies to overcome T cell-dependent immune dysregulations in COVID-19

Coronavirus disease 2019 (COVID-19) pandemic has been an important global interest that affected millions of people, and it requires a deep investigation the immunology for developing further therapeutic applications. Adoptive T cell therapy promises to address cell-dependent immune dysregulation in COVID-19 patients by generation specific clones against virus-specific antigens. Additionally, targeting B protection through vaccines, which have developed recent year, possessed sufficient prevention spreading virus, since cases deaths related tend decrease after vaccination. However, adoptive therapies are now encouraging scientists deal with pathological challenges like inadequate response or lymphopenia, they most frequent outcome severe infection, especially immunocompromized patients. In this review, current knowledge immunopathology was aimed be highlighted along responses SARS-CoV-2 comprise basis therapeutics. Moreover, therapeutics treatment strategies were discussed evaluate possible agents. Furthermore, use representing emerging approach purposed presented comprehensively infection. Even though studies needed fully understand order develop provide long term efficient protection, meet demand large population people who suffer immunocompromization, considering previous usage technique different infectious diseases.